ONWARD Medical, a NeuroTech company focused on restoring movement for individuals with spinal cord injuries, has secured €40.6 million in a follow-on capital raise through a private placement. This funding round, which saw EQT Life Sciences invest €25 million, will be allocated 40% to the development of its investigational ARC-IM® System and 30% to expanding sales for its FDA-approved ARC-EX® System. The net proceeds are projected to extend the company's cash runway into Q1 2028.
Amount: $40.6M
ONWARD Medical capital increase — ONWARD Medical